Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6990)

INSIDE INFORMATION
GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION BY THE COMPANY

This announcement is made by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated September 19, 2025 and March 27, 2026 (the "**Announcements**") in relation to the proposed implementation of the H Share Full Circulation of up to 3,572,088 domestic shares and 4,642,190 unlisted foreign shares of the Company. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

The Company has applied to the Stock Exchange for the approval (the "**Listing Approval**") of the listing of and the permission to deal in 8,214,278 H Shares (the "**Converted H Shares**"), representing the total number of domestic shares and unlisted foreign shares of the Company to be converted under the Conversion and Listing. The Board is pleased to announce that the Listing Approval was granted by the Stock Exchange on April 2, 2026.

Based on the total share capital of the Company as of the date of this announcement, the Converted H Shares represent approximately 3.52% of the total share capital of the Company, and accordingly, the Company's H shares will increase from 69.80% to 73.32%, domestic shares will decrease from 28.21% to 26.68%, and unlisted foreign shares will decrease from 1.99% to 0.00%, of the total share capital of the Company as a result of completion of the Conversion and Listing.

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and Listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, April 8, 2026

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.